[Transpupillary thermotherapy for occult choroidal neovascularizations].
OBJECTIVE
This contribution describes the results of transpupillary thermotherapy (TTT) for age-related exudative macular degeneration (AMD) with regression.


METHODS
In exudative AMD with occult choroidal neovascularization (CNV), transpupillary thermotherapy (TTT) was performed using a diode laser (Iridex) in unselected patients. Before therapy and 1, 3, and 6 months after the initial treatment the patients were examined clinically. Additionally threshold testing in the 10 degrees field (Humphrey) and fluorescein angiographies were documented at all check-ups.


RESULTS
With respect to vision, differences in the slope of the regression lines between small, medium, and large CNV were significant (p<0.001). The slope of the regressions lines was significant except for small CNV. Regarding the 10 degrees field (Humphrey), there were no statistical differences in the slope of the regression lines (p=0.867).


CONCLUSIONS
Transpupillary thermotherapy with small CNV did not show a statistically significant decrease of VA. Thus, in clinical terms early treatment of occult CNV with TTT seems to be able to prevent a further loss of visual acuity.
Weber
U
U
Augenklinik des Klinikums Braunschweig, Akademisches Lehrkrankenhaus der Medizinischen Hochschule, Hannover. u.weber@klinikum-braunschweig.de
Hecker
H
H
D000368:Aged; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000601:surgery*; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008268:Macular Degeneration / Q000175:diagnosis / Q000601:surgery*; D019721:Ophthalmoscopes; D011680:Pupil; D019233:Retreatment; D016896:Treatment Outcome; D014787:Vision Tests; D014794:Visual Fields / Q000502:physiology
Am J Ophthalmol. 2001 Jul;132(1):85-93
11438059
Lasers Med Sci. 2003;18(1):43-4
12627272
Am J Ophthalmol. 2002 Dec;134(6):822-7
12470749
Am J Ophthalmol. 2001 May;131(5):541-60
11336929
Ophthalmic Surg Lasers. 2000 Sep-Oct;31(5):359-73
11011704
Ophthalmology. 2002 Jun;109(6):1098-104
12045050
Am J Ophthalmol. 2003 Sep;136(3):407-18
12967792
Br J Ophthalmol. 2001 Feb;85(2):173-8
11159481
Ophthalmology. 1999 Oct;106(10):1908-14
10519584
Klin Monbl Augenheilkd. 2002 Apr;219(4):250-3
12022011
Semin Ophthalmol. 2001 Jun;16(2):97-100
15491011
Semin Ophthalmol. 2001 Jun;16(2):90-6
15491010
Semin Ophthalmol. 2001 Jun;16(2):86-9
15491009
Semin Ophthalmol. 2001 Jun;16(2):70-80
15491007
Ophthalmologe. 2003 Feb;100(2):111-4
12589454
Acta Ophthalmol Scand. 2003 Apr;81(2):110-7
12752047
Invest Ophthalmol Vis Sci. 2001 Jan;42(1):229-34
11133873
Arch Ophthalmol. 2003 Jun;121(6):817-20
12796252
Curr Opin Ophthalmol. 2001 Jun;12(3):212-5
11389349
Eur J Ophthalmol. 2003 Jun;13(5):453-60
12841568
Invest Ophthalmol Vis Sci. 2003 May;44(5):2133-40
12714653
Invest Ophthalmol Vis Sci. 1998 Feb;39(2):385-90
9477998
Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3337-40
11726642
Semin Ophthalmol. 2001 Jun;16(2):81-5
15491008
Semin Ophthalmol. 1999 Mar;14(1):11-8
10790571
Acta Ophthalmol Scand. 2002 Apr;80(2):136-43
11952478
Am J Ophthalmol. 2001 May;131(5):662-4
11336949
Curr Opin Ophthalmol. 2003 Jun;14(3):155-8
12777935
Arch Ophthalmol. 1999 Oct;117(10 ):1329-45
10532441
Retina. 2001;21(2):172-3
11321145
Semin Ophthalmol. 2001 Jun;16(2):66-9
15491006
Am J Ophthalmol. 2002 Nov;134(5):765-8
12429257
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):320-4
10634637